NASDAQ:FURX - Furiex Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Furiex Pharmaceuticals, Inc. is a drug development collaboration company. The Company's product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas. Its programs include Priligy, Alogliptin Nesina, Alogliptin/Actose Combination, Alogliptin/Metformin Combination, Fluoroquinolone, Mu Delta and PPD 10558. In November 2011, it acquired full exclusive license rights to develop and commercialize the compound MuDelta under its existing development and license agreement with Janssen Pharmaceutica N.V. Effective July 2, 2014 Forest Laboratories Inc, a unit of Actavis PLC, acquired the entire share capital of Furiex Pharmaceuticals Inc.

Receive FURX News and Ratings via Email

Sign-up to receive the latest news and ratings for FURX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryLife Sciences Tools & Services
SectorN/A
Current SymbolNASDAQ:FURX
CUSIP36106P10
WebN/A
Phone+1-919-4567800

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Furiex Pharmaceuticals (NASDAQ:FURX) Frequently Asked Questions

What is Furiex Pharmaceuticals' stock symbol?

Furiex Pharmaceuticals trades on the NASDAQ under the ticker symbol "FURX."

Has Furiex Pharmaceuticals been receiving favorable news coverage?

News coverage about FURX stock has been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Furiex Pharmaceuticals earned a coverage optimism score of 1.7 on InfoTrie's scale. They also assigned news stories about the healthcare company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days.

How do I buy shares of Furiex Pharmaceuticals?

Shares of FURX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Furiex Pharmaceuticals?

Furiex Pharmaceuticals' mailing address is 3900 Paramount Pkwy Ste 150, MORRISVILLE, NC 27560-5401, United States. The healthcare company can be reached via phone at +1-919-4567800.


MarketBeat Community Rating for Furiex Pharmaceuticals (NASDAQ FURX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  90 (Vote Outperform)
Underperform Votes:  73 (Vote Underperform)
Total Votes:  163
MarketBeat's community ratings are surveys of what our community members think about Furiex Pharmaceuticals and other stocks. Vote "Outperform" if you believe FURX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FURX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel